Lucis Secures $20 Million for AI-Driven Preventive Healthcare

Lucis, the platform aiming to revolutionize preventive healthcare through artificial intelligence, has announced the closing of a $20 million Series A funding round. The operation was led by Singular, with participation from General Catalyst, Y Combinator, and several angel investors, including backers of Runna, Céline Lazorthes (Resilience), and Manu Lecomte. This new capital follows an $8 million seed round raised just four months ago, bringing the company's total funding to $28 million.

Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis aims to provide individuals with a comprehensive, data-driven view of their health. The goal is to shift the paradigm from late-stage diagnosis to proactive prevention, a growing need in a healthcare sector that often intervenes only after symptoms appear.

The AI Model and Sensitive Data Management

The Lucis platform stands out for its ability to analyze over 110 blood biomarkers, covering crucial areas such as metabolic health, hormone levels, cardiovascular risk, inflammation, and nutrient levels. This data is then integrated into an AI-powered "companion" application, which combines the results with longitudinal data and the user's medical context. The outcome is personalized guidance ranging from nutrition and supplementation to lifestyle changes and follow-up testing.

A fundamental aspect of the service is that recommendations are continuously refined as new data becomes available and are always reviewed by medical specialists. This hybrid approach, combining the power of AI with human clinical oversight, helps users understand not only what the data indicates but, more importantly, what concrete actions to take. The management of such sensitive health data raises critical questions regarding data sovereignty and regulatory compliance, such as GDPR. For organizations operating in this sector, choosing an on-premise or hybrid deployment for AI workloads can become a strategic priority, ensuring tighter control over infrastructure and data.

Market Impact and Growth

Early data collected from Lucis's growing user base, which exceeds 10,000 individuals, shows significant results in both health outcomes and engagement. Among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication. Furthermore, over 80% of users opted to retest, suggesting continued engagement with the platform and their health data.

A particularly relevant finding from initial testing is that 99.9% of users had at least one biomarker outside optimal ranges, often without prior awareness. This highlights how easily potential health risks can go unnoticed without regular monitoring. Since its launch in 2025, Lucis has reached over 10,000 users across France, the UK, Ireland, and Portugal, and has delivered over one million biomarker tests. The company has also built a community of thousands of members and established partnerships with major laboratory groups such as Eurofins and Randox.

Future Prospects and Implications for AI in Healthcare

Maxime Berthelot, co-founder and CEO of Lucis, highlighted the devastating impact of late-stage diagnoses, stating that the science for prevention already exists, but a system designed to act before symptoms appears is missing. Lucis's vision is to make prevention the default, not a privilege, by combining biomarker data and AI-driven clinical insights to catch what the traditional system misses.

Jeremy Uzan, co-founder and General Partner at Singular, emphasized that success in Europe's preventive health sector will depend on platforms that can unite clinical credibility with AI at scale. He praised Lucis's remarkable velocity in reaching 10,000 users in under a year and delivering measurable outcomes, building a compounding data advantage. Lucis plans to expand into Spain, Germany, and Italy by the end of 2026, continuing to invest in personalization, longitudinal monitoring, and clinical safety. For CTOs and infrastructure architects evaluating the adoption of AI solutions in regulated sectors like healthcare, the choice between on-premise and cloud deployment is crucial for balancing TCO, data sovereignty, and compliance requirements. AI-RADAR offers analytical frameworks on /llm-onpremise to support these strategic decisions.